Do we need more long-term outcome trials for the treatment of hypertension?

Journal of the Royal College of Physicians of Edinburgh

Volumn 41, Issue 1, 2011, Pages 30-37

  Beevers, D G ^a   McInnes, G T ^b  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cost; Desirability; Feasibility; Hypertension; Long term trials

Indexed keywords

ALISKIREN; AMBRISENTAN; AMLODIPINE; BETANIDINE; BOSENTAN; GUANETHIDINE; HYDROCHLOROTHIAZIDE; METHYLDOPA; MOXONIDINE; PENTOLONIUM TARTRATE; THIAZIDE DIURETIC AGENT;

ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); DIET THERAPY; DISEASE SEVERITY; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FOLLOW UP; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; PREHYPERTENSION; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; HYPERTENSION;

EID: 79959521429     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2011.109     Document Type: Article

References (36)

1. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-98.
2. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-64.
3. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-64. doi:10.1016/S0140-6736(97)05381-6
4. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-98. doi:10.1056/NEJMoa0801369
5. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:1245-53. doi:10.1136/bmj.b1665
6. Blood Pressure Lowering Treatment Trialist Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-35. doi:10.1016/S0140-6736(03)14739-3
7. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial -Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. doi:10.1016/S0140-6736(05)67185-1
8. Staessen JA, Birkenhäger WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366:869-71. doi:10.1016/S0140-6736(05)67147-4
9. Weber M, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment in clinical events in the VALUE trial. Lancet 2004; 363:2049-51. doi:10.1016/S0140-6736(04)16456-8
10. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial) a randomised controlled trial. Lancet 2007; 370:829-40. doi:10.1016/S0140-6736(07)61303-8
11. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-59. doi:10.1056/NEJMoa0801317
12. TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-83. doi:10.1016/S0140-6736(08)61242-8
13. Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-37. doi:10.1056/NEJMoa0804593
14. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-13. doi:10.1016/S0140-6736(02)11911-8
15. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53. doi:10.1056/NEJM200001203420301
16. Svensson P, de Faire U, Sleight P et al. Comparative effects of ramipril on ambulatory and office blood pressure: a HOPE substudy. Hypertension 2001; 38: E28-E32. doi:10.1161/hy1101.099502
17. Dahlöf B, Devereux RB, Kjeldson SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. doi:10.1016/S0140-6736(02)08089-3
18. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-53. doi:10.1016/S0140-6736(05)67573-3
19. Messerli FH, Beevers DG, Franklin SS et al. Beta-blockers in hypertension: the emperor has no clothes - an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens 2003; 16:870-3. doi:10.1016/S0895-7061(03)01017-3
20. Zanchetti A. Evidence-based medicine in hypertension. What type of evidence? J Hypertens 2005; 23:1113-20. doi:10.1097/01.hjh.0000170370.41387.1b
21. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581-4. doi:10.1016/S0140-6736(87)90231-5
22. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 1: 861-5. doi:10.1016/S0140-6736(79)91274-1
23. Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-93.
24. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-8. doi:10.1016/S0140-6736(03)14286-9
25. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004; 292:2217-26. doi:10.1001/jama.292.18.2217
26. Zanchetti A, Hansson L, Clement D et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT Study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21:797-804. doi:10.1097/00004872-200304000-00024
27. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-31. doi:10.1016/S0140-6736(04)16451-9
28. Brown MJ, McInnes GT, Papst CE et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377:312-20. doi: 10.1016/S0140-6736(10)62003-X
29. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419-23. doi:10.1136/bmj.326.7404.1419
30. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-58. doi:10.1016/S0140-6736(03)12948-0
31. McInnes GT. Antioxidants in hypertension: another false dawn? J Hypertens 2005; 23:1963-6. doi:10.1097/01.hjh.0000186834.86867.96
32. Lonn E, Bosch J, Teo KK et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges and future directions. Circulation 2010; 122:2078-88. doi:10.1161/CIRCULATIONAHA.109.873232
33. Mancia G. Role of outcome trials in providing information on antihypertensive treatment: importance and limitations. Am J Hypertens 2006; 19:1-7. doi:10.1016/j.amjhyper.2005.10.009
34. Paul L, Hastie CE, Li WS et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010; 55:567-74. doi:10.1161/HYPERTENSIONAHA.109.144808
35. Zanchetti A, Mancia G, Black HR et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009: 27:673-9. doi:10.1097/HJH.0b013e3283298ea2
36. Verdecchia P, Gentile G, Angeli F et al. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens 2010; 28:1356-65. doi:10.1097/HJH.0b013e328338e2bb